HOME >> BIOLOGY >> NEWS
A Jekyll-and-Hyde enzyme's role in Alzheimer's

Researchers have discovered how a brain enzyme important in the development and maintenance of learning and memory also plays a key role in the death of neurons in neurodegenerative disorder such as Alzheimer's disease (AD). They found that the enzyme's transformation from Jekyll to Hyde may be due to abnormal activation of the brain's mechanism to compensate for the damage from such diseases. This compensatory mechanism may also function in normal aging, they said.

In their article in the December 8, 2005, issue of Neuron, Li-Huei Tsai and colleagues said their findings in mice could offer a model to study how normal neural mechanisms can go awry to contribute to the brain degeneration of AD.

The researchers' studies concentrated on a key brain regulatory enzyme called Cdk5. Elevated levels of Cdk5 had been found in the brains of AD patients, as well as elevated levels of a regulatory protein called p25 that is known to hyperactivate Cdk5. Researchers had found that the hyperactivating p25 is produced when the normal regulatory protein for Cdk5, called p35, is snipped into the shorter p25 by another enzyme.

In their experiments, the researchers used mice in which they could switch on p25 at will in the brain's learning and memory center, the hippocampus. In these mice, they found that switching on p25 for only two weeks actually enhanced learning and memory compared to normal mice. The two-week p25 mice could learn more quickly to associate a tone or environment with a mild electrical shock and to find a platform submerged in a pool of murky water.

In contrast, found the researchers, mice in which p25 had been switched on for six weeks showed impaired learning and memory in these tasks. Physiological studies showed that these mice showed significant brain atrophy and loss of hippocampal neurons. The researchers also showed that the two-week pulse of p25 did not cause neurodegeneration and had long-lasting effects on enhancing memory.
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
7-Dec-2005


Page: 1 2

Related biology news :

1. Nobel Laureate finds elegant explanation for DNA transcribing enzymes high fidelity
2. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
3. Link identified between Alzheimers disease and glaucoma
4. UCF research links proteins, stem cells and potential Alzheimers treatment
5. Journal of Alzheimers Disease achieves significant impact factor
6. Alzheimers prevention role discovered for prions
7. Cloned pigs help scientists towards a breakthrough in Alzheimers
8. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
9. Paving the way toward a vaccine against Alzheimers disease
10. Genetic fellow traveler discovered in Alzheimers
11. New clues to stroke role in Alzheimers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Jekyll and Hyde enzyme role Alzheimer

(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 ... of Debiopharm Group ™ , a Swiss-based global ... unmet medical needs as well as companion ... the investigational compounds Debio 1143 (SMAC mimetic) and ... at the 2015 Annual meeting of the ...
(Date:4/16/2015)... Washington (PRWEB) April 16, 2015 ... Applied Cancer Science and Resolution Bioscience, Inc. today ... to co-develop a novel, blood-based, clinic ready, Next ... cancer (NSCLC). The collaboration is the first to ... RET, and ROS1 fusions in blinded plasma samples ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
Cached News: